Table 3.
Selected combination trials for renal cell carcinoma incorporating blocking monoclonal antibodies targeting PD-1 or PD-L1
| Combination drug class | Treatment | ClinicalTrials.gov identifier |
|---|---|---|
| Vaccine | CT-011 + DC/RCC fusion vaccine | NCT01441765 |
| Checkpoint inhibitor | Nivolumab + ipilimumab | NCT01472081 |
| MEDI4736 + tremelimumab | NCT01975831 | |
| Nivolumab + anti-LAG-3 | NCT01968109 | |
| MK-3475 + ipilimumab | NCT02089685 | |
| AMP-514 + MEDI4736 | NCT02118337 | |
| Cytokine | MK-3475 + PEG-IFN-α | NCT02089685 |
| Antiangiogenic | Nivolumab + sunitinib or pazopanib | NCT01472081 |
| MK-3475 + pazopanib | NCT02014636 | |
| MPDL3280A + bevacizumab | NCT01984242 |
Abbreviations: PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; DC, dendritic cell; RCC, renal cell carcinoma; PEG-IFN-α, pegylated interferon α-2b.